Cilnidipine exhibited significant antiviral activity against Influenza A virus, improving the survival rate of infected mice to 90% at a dose of 50 mg/kg compared to 0% in the untreated virus group.
Does cilnidipine inhibit Influenza A virus infection in preclinical models?
Cilnidipine, a calcium channel blocker, demonstrates promising antiviral activity against Influenza A virus by inhibiting viral internalization and membrane fusion in preclinical models.
Tasa de eventos absoluta: 90% vs 0%
BACKGROUND: ⁺ channel blockers (CCBs) promising candidates for antiviral agents. METHODS: The in vitro antiviral activity of cilnidipine was evaluated using MTT assays, qRT-PCR, plaque assays, and western blotting. Mechanistic studies involved time-of-addition, viral internalization, pseudovirus neutralization, and HA (hemagglutinin) syncytium assays. For in vivo analysis, BALB/c mice were intranasally infected to evaluate the effects of cilnidipine on viral titer, lung index, pulmonary inflammatory mediators, and survival rate. RESULTS: In vitro, cilnidipine exhibits antiviral activity against IAV during the early stages of infection. It disrupts clathrin- and caveolin-mediated endocytosis to inhibit the internalization of IAV and interacts with the viral HA2 subunit to impede virus membrane fusion. Additionally, cilnidipine suppresses the PI3K-AKT and p38 MAPK pathways activated by IAV infections. In vivo, cilnidipine reduces virus titers and lung index, ameliorates lung pathology, and inhibits pulmonary inflammatory mediator expression, improving survival rates. CONCLUSIONS: These findings highlight the promising anti-IAV properties of cilnidipine both in vitro and in vivo, suggesting its potential as a clinical agent for emergencies against influenza outbreaks.
Li et al. (Sun,) conducted a other in Influenza A virus infection. Cilnidipine vs. Vehicle control (0.5% CMC) or Oseltamivir (60 mg/kg/d) was evaluated on Survival rate at 14 days post-infection. Cilnidipine exhibited significant antiviral activity against Influenza A virus, improving the survival rate of infected mice to 90% at a dose of 50 mg/kg compared to 0% in the untreated virus group.